Condition Database
Conditions with pharmacogenomic relevance for peptide therapeutic design. Each profile covers genetic variants, current treatments, and computational peptide approaches.
The most common neurodegenerative disease, characterized by progressive memory loss, cognitive decline, and amyloid-beta plaque accumulation. Genetic factors account for 60-80% of risk, with APOE4 being the strongest common risk allele.
A metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction. TCF7L2 variants are the strongest common genetic risk factors. GLP-1 receptor agonist peptides have revolutionized treatment.
Genetic variation in VKORC1 and CYP2C9 determines warfarin dose requirements. FDA recommends pharmacogenomic testing, and genotype-guided dosing reduces bleeding events by 30%. It is the most established pharmacogenomic application in clinical practice.
Genetic variation in cytochrome P450 enzymes (CYP2D6, CYP2C19, CYP2C9) creates a spectrum from ultra-rapid to poor metabolizers. This affects ~25% of all prescribed medications and is the foundation of clinical pharmacogenomics.
Elevated blood homocysteine due to MTHFR variants (C677T, A1298C) affecting folate metabolism. Associated with cardiovascular disease, neural tube defects, and potential cognitive effects. The most common pharmacogenomic condition worldwide.
Genetic variation in COMT (Val158Met) and OPRM1 (A118G) creates a wide spectrum of pain sensitivity and opioid analgesic requirements. Personalized pain management is one of the most promising applications of pharmacogenomics.
A monogenic disorder caused by the HBB rs334 (Glu6Val) mutation in beta-globin. Hemoglobin S polymerizes under deoxygenation, causing vaso-occlusive crises, chronic hemolysis, and organ damage. Gene therapy and anti-sickling approaches are transforming treatment.
BRCA1 and BRCA2 mutations cause hereditary breast and ovarian cancer syndrome (HBOC). Lifetime breast cancer risk reaches 65-85% for BRCA1 carriers. PARP inhibitors exploit synthetic lethality in BRCA-deficient tumors.
Genetic variants in APOE, AGT, AGTR1, and lipid metabolism genes contribute to cardiovascular risk. Pharmacogenomics guides anticoagulant, antiplatelet, and antihypertensive therapy selection.
Essential hypertension affects 1.3 billion adults worldwide. AGT (rs699) and AGTR1 (rs5186) variants modulate the renin-angiotensin-aldosterone system (RAAS), the primary pharmacological target for blood pressure control.
MC1R variants, particularly rs1805007 (Arg151Cys), increase melanoma risk 2-4 fold independent of UV exposure by impairing DNA repair in melanocytes. Also affects anesthesia requirements.
Genetic variation in dopamine (DRD2/ANKK1) and opioid (OPRM1) receptor systems creates differential vulnerability to substance use disorders. Personalized pharmacotherapy guided by genotype is an emerging paradigm.